<DOC>
	<DOCNO>NCT00000677</DOCNO>
	<brief_summary>To assess safety effectiveness SCH 39304 primary treatment acute cryptococcal meningitis HIV-infected patient . Safety effectiveness maintenance therapy follow successful treatment acute disease also evaluate . Cryptococcal meningitis significant cause illness death HIV-infected patient . Intravenous amphotericin B effective acute disease relapse occur majority patient . Maintenance therapy recommend must balance multiple toxicity drug use problem associated weekly administration intravenous therapy . Treatments equally effective less toxic traditional method need , especially oral therapy . SCH 39304 orally active antifungal drug animal study active wide range systemic fungal infection include infection due Cryptococcus . Features SCH 39304 suggest might value treatment cryptococcal meningitis .</brief_summary>
	<brief_title>SCH 39304 Therapy Acute Cryptococcal Meningitis HIV-Infected Patients Followed Maintenance Therapy</brief_title>
	<detailed_description>Cryptococcal meningitis significant cause illness death HIV-infected patient . Intravenous amphotericin B effective acute disease relapse occur majority patient . Maintenance therapy recommend must balance multiple toxicity drug use problem associated weekly administration intravenous therapy . Treatments equally effective less toxic traditional method need , especially oral therapy . SCH 39304 orally active antifungal drug animal study active wide range systemic fungal infection include infection due Cryptococcus . Features SCH 39304 suggest might value treatment cryptococcal meningitis . HIV-infected patient diagnosis acute cryptococcal meningitis , previously untreated relapse follow successfully treat acute episode , enrol study . SCH 39304 administer orally daily 3 day follow low dose daily 12 week . Patients respond primary therapy randomize receive SCH 39304 maintenance therapy high dose weekly low dose daily 12 month protocol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Sch 39304</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Currently approve antiviral therapy . Maintenance therapy cytomegalovirus retinitis toxoplasmosis . Rifampin . Isoniazid . Dilantin barbiturates investigator agree rigorously monitor anticonvulsant drug level . Coumarintype anticoagulant investigator agree rigorously monitor prothrombin time . Prophylactic treatment Pneumocystis carinii pneumonia ( PCP ) . Concurrent Treatment : Allowed : Local radiotherapy mucocutaneous Kaposi 's sarcoma . Prior Medication : Allowed : Amphotericin B , 1 mg/kg , previous 7 day . Patients must HIV positive 2 methodology either primary cryptococcal meningitis prior anticryptococcal therapy relapse disease prior therapy . Prior therapy cryptococcal meningitis limit approved drug . Written inform consent either patient patient 's parent legal guardian require . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : History hypersensitivity imidazole azole compound . Central nervous system disease . Acute opportunistic infection . Underlying condition opinion investigator could preclude assessment response . Concurrent Medication : Excluded : Systemic antifungal drug study drug . Any investigational drug treatment IND drug . Oral hypoglycemic agent . Oral contraceptive . Cytotoxic chemotherapy . Patients follow exclude : Unable take oral medication . Concurrent central nervous system disease opinion investigator would interfere assessment response . Concurrent acute opportunistic infection require therapy ( patient develop acute opportunistic infection initiation study medication may remain study medication ) . Prior Medication : Excluded within 7 day study entry : Amphotericin B , &gt; 1 mg/kg .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1994</verification_date>
	<keyword>Sch 39304</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>